purposes radionuclide 211at conjugated cd20 targeting chimeric monoclonal antibody rituximab studied estimate radiation dose components lymphoma bone marrow bm cells exposed vitro b calculate mean absorbed radiation doses various normal tissues mice following intravenous injection materials methods cells rael normal human bm cells incubated increasing concentrations radioimmunoconjugate based binding kinetics measured cellular nuclear diameters radiation doses calculated using microdosimetric methods results targeting rael cells extensive stable compared binding bm cells absorbed radiation doses activity initial activity concentration NUMBER kbq NUMBER NUMBER gy rael bm cells respectively comparison contribution unbound conjugate medium 1h exposure NUMBER NUMBER gy d0 value rael cells NUMBER gy NUMBER gy bm cells corresponding d0 values NUMBER NUMBER gy single exposure external 60co mean absorbed doses NUMBER NUMBER NUMBER gy blood lungs heart calculated mice injected 54kbq conclusion despite higher inherent sensitivity bm cells related radioactivity concentrations logs greater cell kill rael cells illustrating nature targeting alpha emitting b lymphoma 211at rituximab cell bound ml NUMBER gamma rays g NUMBER 211at rituximab alpha irradiation 211at rituximab tumour specific